The U.S. Air Force has developed a vascular injury shunt for treating traumatic wounds and hemorrhage control, which allows field surgeons to save lives and limbs that would otherwise be lost.
The patented vascular shunt design is available to companies that would manufacture it for commercial sales.
The device is a temporary vascular shunt (a small caliber hollow plastic tube), which is placed in the uninjured segments of blood vessel above and below the disruption to restore blood flow until conditions improve and the shunt can be removed and repair performed.
Currently available vascular shunts were designed for use in age-related vascular disease treatment and not traumatic injury. Wartime and civilian reports confirm the effectiveness of vascular shunts; however, at present their use is limited.
The Air Force shunt was designed by combat surgeons and military researchers to minimize the risk of complications, ensure its adaptability to the unique needs of patients, and allow infusion of therapeutic (therapeutic reperfusion) or contrast agents (angiography) into the injured limb via an injection port. The Air Force is pursuing FDA approvals.
- Designed for rapid insertion by broad range of surgeons
- Early reperfusion of damaged extremity leads to improved functional outcomes for patients
- First shunt designed for extremity vascular injury
- Preclinical studies published in peer-reviewed journals have demonstrated efficacy and safety of early restoration of extremity perfusion
- Businesses can commercialize the invention by licensing U.S. Patent 8,251,943 from the Air Force
- License fees paid to the Air Force are negotiable
- Porcine studies and capabilities document, and prototype available for review
- TechLink guides businesses through evaluation and licensing; services provided at no charge